{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:34Z","timestamp":1793199994038,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12072-025-10965-6","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:51:38Z","timestamp":1764611498000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soek-Siam","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumali","family":"Efe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Isayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"10965_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12072-016-9767-9","volume":"10","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016;10:909\u2013915","journal-title":"Hepatol Int"},{"key":"10965_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3350\/cmh.2023.0087","volume":"29","author":"Korean Association for the Study of the Liver (KASL)","year":"2023","unstructured":"Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of autoimmune hepatitis 2022. Clin Mol Hepatol. 2023;29:542\u2013592","journal-title":"Clin Mol Hepatol"},{"key":"10965_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/hepr.13776","volume":"52","author":"H Ohira","year":"2022","unstructured":"Ohira H, et al. Clinical practice guidelines for autoimmune hepatitis. Hepatol Res. 2022;52:571\u2013585","journal-title":"Hepatol Res"},{"key":"10965_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12072-021-10170-1","volume":"15","author":"G Wang","year":"2021","unstructured":"Wang G, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15:223\u2013257","journal-title":"Hepatol Int"},{"key":"10965_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102280","volume":"65","author":"JW Hahn","year":"2023","unstructured":"Hahn JW, et al. Global incidence and prevalence of autoimmune hepatitis, 1970\u20132022: a systematic review and meta-analysis. EClinicalMedicine. 2023;65: 102280","journal-title":"EClinicalMedicine"},{"key":"10965_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100125","volume":"4","author":"K Zachou","year":"2021","unstructured":"Zachou K, et al. Impact of genetic and environmental factors on autoimmune hepatitis. J Transl Autoimmun. 2021;4: 100125","journal-title":"J Transl Autoimmun"},{"key":"10965_CR7","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/liv.14944","volume":"41","author":"C Lammert","year":"2021","unstructured":"Lammert C, et al. Environmental risk factors are associated with autoimmune hepatitis. Liver Int. 2021;41:2396\u20132403","journal-title":"Liver Int"},{"key":"10965_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413578","author":"C Sirbe","year":"2021","unstructured":"Sirbe C, et al. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222413578","journal-title":"Int J Mol Sci"},{"key":"10965_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s12072-024-10714-1","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Harada K. Acute presentation of autoimmune hepatitis -from acute hepatitis to ALF and ACLF. Hepatol Int. 2024;18:1385\u20131395","journal-title":"Hepatol Int"},{"key":"10965_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116:878\u2013898","journal-title":"Am J Gastroenterol"},{"key":"10965_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176","journal-title":"Hepatology"},{"issue":"2","key":"10965_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2025.03.017","volume":"83","author":"G Dalekos","year":"2025","unstructured":"Dalekos G, Gatselis N, Drenth JP, Heneghan M, J\u00f8rgensen M, Lohse AW, et al. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025;83(2):453\u2013501","journal-title":"J Hepatol"},{"key":"10965_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353\u2013390","journal-title":"Hepatol Int"},{"key":"10965_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101871","volume":"46","author":"JC Duclos-Vall\u00e9e","year":"2022","unstructured":"Duclos-Vall\u00e9e JC, et al. Best practice guidelines for France regarding the diagnosis and management of autoimmune hepatitis. Clin Res Hepatol Gastroenterol. 2022;46: 101871","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10965_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12072-024-10761-8","volume":"19","author":"JW Wu","year":"2025","unstructured":"Wu JW, et al. Rheumatoid factor levels indicate cryoglobulinemia severity in hepatitis B e antigen-negative hepatitis B virus carriers: a 7-year prospective cohort study. Hepatol Int. 2025;19:118\u2013130","journal-title":"Hepatol Int"},{"key":"10965_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064891","volume":"8","author":"ML Chang","year":"2013","unstructured":"Chang ML, et al. Occult and overt HBV co-infections independently predict postoperative prognosis in HCV-associated hepatocellular carcinoma. PLoS ONE. 2013;8: e64891","journal-title":"PLoS ONE"},{"key":"10965_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3109\/00365521.2013.772231","volume":"48","author":"C Efe","year":"2013","unstructured":"Efe C, et al. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B\/C. Scand J Gastroenterol. 2013;48:504\u2013508","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"10965_CR18","first-page":"175","volume":"7","author":"Z Michalska","year":"2001","unstructured":"Michalska Z, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001;7(Suppl 1):175\u2013180","journal-title":"Med Sci Monit"},{"key":"10965_CR19","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1111\/jgh.16736","volume":"39","author":"ML Chang","year":"2024","unstructured":"Chang ML, et al. Distinct characteristics of various autoimmune liver diseases: a 22-year hospital-based study in Taiwan. J Gastroenterol Hepatol. 2024;39:2835\u20132844","journal-title":"J Gastroenterol Hepatol"},{"key":"10965_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12325-021-01983-5","volume":"39","author":"S Batskikh","year":"2022","unstructured":"Batskikh S, et al. May previous hepatitis B virus infection be involved in etiology and pathogenesis of autoimmune liver diseases? Adv Ther. 2022;39:430\u2013440","journal-title":"Adv Ther"},{"key":"10965_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"BS Sheena","year":"2022","unstructured":"Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7:796\u2013829","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10965_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1478-3231.2008.01851.x","volume":"29","author":"SP Georgiadou","year":"2009","unstructured":"Georgiadou SP, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int. 2009;29:434\u2013442","journal-title":"Liver Int"},{"issue":"6","key":"10965_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jmii.2019.04.009","volume":"53","author":"XX Chen","year":"2019","unstructured":"Chen XX, et al. Occult HBV infection in patients with autoimmune hepatitis: a virological and clinical study. J Microbiol Immunol Infect. 2019;53(6):946\u2013954","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"10965_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.14744\/nci.2019.47701","volume":"7","author":"F Enc","year":"2020","unstructured":"Enc F, Ulasoglu C. A case of autoimmune hepatitis following pegylated interferon treatment of chronic hepatitis delta. North Clin Istanb. 2020;7(4):407\u2013410. https:\/\/doi.org\/10.14744\/nci.2019.47701","journal-title":"North Clin Istanb"},{"key":"10965_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","volume":"13","author":"EI Rigopoulou","year":"2013","unstructured":"Rigopoulou EI, et al. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol. 2013;13:127\u2013135","journal-title":"Ann Hepatol"},{"key":"10965_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1574-6976.1994.tb00095.x","volume":"14","author":"M Lenzi","year":"1994","unstructured":"Lenzi M. Autoimmune hepatitis and hepatitis C virus infection. FEMS Microbiol Rev. 1994;14:247\u2013252","journal-title":"FEMS Microbiol Rev"},{"key":"10965_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000060477","volume":"62","author":"AW Lohse","year":"1998","unstructured":"Lohse AW, Gerken G, Meyer zum B\u00fcschenfelde KH. Autoimmune hepatitis and hepatitis C virus infection. Curr Stud Hematol Blood Transfus. 1998;62:152\u2013160","journal-title":"Curr Stud Hematol Blood Transfus"},{"key":"10965_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0753-3322(99)80095-X","volume":"53","author":"FL Dumoulin","year":"1999","unstructured":"Dumoulin FL, et al. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999;53:242\u2013254","journal-title":"Biomed Pharmacother"},{"key":"10965_CR29","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1038\/s41598-020-71296-0","volume":"10","author":"A Takahashi","year":"2020","unstructured":"Takahashi A, et al. Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan. Sci Rep. 2020;10:14250","journal-title":"Sci Rep"},{"key":"10965_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6470847","volume":"2022","author":"\u00c1 Urz\u00faa","year":"2022","unstructured":"Urz\u00faa \u00c1, Pizarro C, Gajardo A, Poniachik R, Pavez C, Cattaneo M, et al. Autoimmune hepatitis with acute presentation: clinical, biochemical, and histological features of 126 patients. Can J Gastroenterol Hepatol. 2022;2022: 6470847. https:\/\/doi.org\/10.1155\/2022\/6470847","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10965_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671\u2013722","journal-title":"Hepatology"},{"issue":"6","key":"10965_CR32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jhep.2020.12.033","volume":"74","author":"E De Martin","year":"2021","unstructured":"De Martin E, Coilly A, Chazouill\u00e8res O, Roux O, Peron J-M, Houssel-Debry P, et al. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score. J Hepatol. 2021;74(6):1325\u20131334. https:\/\/doi.org\/10.1016\/j.jhep.2020.12.033","journal-title":"J Hepatol"},{"key":"10965_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001549","author":"D Gleeson","year":"2025","unstructured":"Gleeson D, et al. What is the optimal first-line treatment of autoimmune hepatitis? A systematic review with meta-analysis of randomised trials and comparative cohort studies. BMJ Open Gastroenterol. 2025. https:\/\/doi.org\/10.1136\/bmjgast-2024-001549","journal-title":"BMJ Open Gastroenterol"},{"key":"10965_CR34","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.cgh.2021.06.006","volume":"20","author":"F Noguchi","year":"2022","unstructured":"Noguchi F, et al. Early dynamics of MELD scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis. Clin Gastroenterol Hepatol. 2022;20:2641-2643.e2643","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10965_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/hep.30205","volume":"70","author":"L Anand","year":"2018","unstructured":"Anand L, et al. Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy. Hepatology. 2018;70(2):587\u2013596","journal-title":"Hepatology"},{"key":"10965_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/lt.25739","volume":"26","author":"M Heinemann","year":"2020","unstructured":"Heinemann M, et al. Longterm survival after liver transplantation for autoimmune hepatitis: results from the European Liver Transplant Registry. Liver Transpl. 2020;26:866\u2013877","journal-title":"Liver Transpl"},{"key":"10965_CR37","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, et al. Primary biliary cholangitis. Lancet. 2024;404:1053\u20131066","journal-title":"Lancet"},{"key":"10965_CR38","doi-asserted-by":"publisher","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7:e0179","journal-title":"Hepatol Commun"},{"key":"10965_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","volume":"127","author":"C Selmi","year":"2004","unstructured":"Selmi C, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485\u2013492","journal-title":"Gastroenterology"},{"key":"10965_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-021-01836-6","volume":"57","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto K, et al. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study. J Gastroenterol. 2022;57:19\u201329","journal-title":"J Gastroenterol"},{"key":"10965_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3904\/kjim.2019.234","volume":"36","author":"KA Kim","year":"2021","unstructured":"Kim KA, et al. Environmental risk factors and comorbidities of primary biliary cholangitis in Korea: a case-control study. Korean J Intern Med. 2021;36:313\u2013321","journal-title":"Korean J Intern Med"},{"key":"10965_CR42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00535-023-01999-4","volume":"58","author":"KA Kim","year":"2023","unstructured":"Kim KA, et al. Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019. J Gastroenterol. 2023;58:682\u2013692","journal-title":"J Gastroenterol"},{"key":"10965_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/hepr.13342","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49:881\u2013889","journal-title":"Hepatol Res"},{"key":"10965_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.43","volume":"8","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, et al. Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8: e116","journal-title":"Clin Transl Gastroenterol"},{"key":"10965_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13910","author":"JS Cheng","year":"2023","unstructured":"Cheng JS, et al. Characteristic geoepidemiology of primary biliary cholangitis in Taiwan: a nationwide population-based study. Hepatol Res. 2023. https:\/\/doi.org\/10.1111\/hepr.13910","journal-title":"Hepatol Res"},{"key":"10965_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14924","author":"J French","year":"2019","unstructured":"French J, et al. Increasing prevalence of primary biliary cholangitis in Victoria, Australia. J Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1111\/jgh.14924","journal-title":"J Gastroenterol Hepatol"},{"key":"10965_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","volume":"19","author":"M Lamba","year":"2021","unstructured":"Lamba M, Ngu JH, Stedman CAM. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2021;19:573-579.e571","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10965_CR48","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jgh.15329","volume":"36","author":"T Lv","year":"2021","unstructured":"Lv T, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36:1423\u20131434","journal-title":"J Gastroenterol Hepatol"},{"key":"10965_CR49","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/hepr.13910","volume":"53","author":"JS Cheng","year":"2023","unstructured":"Cheng JS, et al. Characteristic geoepidemiology of primary biliary cholangitis in Taiwan: a nationwide population-based study. Hepatol Res. 2023;53:866\u2013877","journal-title":"Hepatol Res"},{"key":"10965_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145\u2013172","journal-title":"J Hepatol"},{"key":"10965_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10276-6","author":"H You","year":"2022","unstructured":"You H, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022. https:\/\/doi.org\/10.1007\/s12072-021-10276-6","journal-title":"Hepatol Int"},{"key":"10965_CR52","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3748\/wjg.v29.i12.1795","volume":"29","author":"EI Rigopoulou","year":"2023","unstructured":"Rigopoulou EI, Bogdanos DP. Role of autoantibodies in the clinical management of primary biliary cholangitis. World J Gastroenterol. 2023;29:1795\u20131810","journal-title":"World J Gastroenterol"},{"key":"10965_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2019.01.005","volume":"99","author":"C Sun","year":"2019","unstructured":"Sun C, et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: is alkaline phosphatase truly a surrogate marker? J Autoimmun. 2019;99:33\u201338","journal-title":"J Autoimmun"},{"key":"10965_CR54","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/hep4.1907","volume":"6","author":"D Ding","year":"2022","unstructured":"Ding D, et al. Immunoglobulin M: a neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase. Hepatol Commun. 2022;6:1403\u20131412","journal-title":"Hepatol Commun"},{"key":"10965_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","volume":"5","author":"RA Shah","year":"2020","unstructured":"Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5:306\u2013315","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10965_CR56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.029","journal-title":"Gastroenterology"},{"key":"10965_CR57","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","volume":"77","author":"C Corpechot","year":"2022","unstructured":"Corpechot C, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022;77:1545\u20131553","journal-title":"J Hepatol"},{"key":"10965_CR58","doi-asserted-by":"publisher","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","volume":"120","author":"KV Kowdley","year":"2025","unstructured":"Kowdley KV, et al. COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol. 2025;120:390\u2013400","journal-title":"Am J Gastroenterol"},{"key":"10965_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102358","volume":"48","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Corpechot C. PPAR agonists in PBC: where do we go from here? Or how to choose between the new and the old. Clin Res Hepatol Gastroenterol. 2024;48: 102358","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10965_CR60","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390:783\u2013794","journal-title":"N Engl J Med"},{"key":"10965_CR61","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390:795\u2013805","journal-title":"N Engl J Med"},{"key":"10965_CR62","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouill\u00e8res","year":"1998","unstructured":"Chazouill\u00e8res O, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (Baltimore, MD). 1998;28:296\u2013301","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10965_CR63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","volume":"41","author":"Q Wang","year":"2013","unstructured":"Wang Q, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun. 2013;41:140\u2013145","journal-title":"J Autoimmun"},{"key":"10965_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103163","volume":"143","author":"R Wang","year":"2024","unstructured":"Wang R, et al. Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis. J Autoimmun. 2024;143: 103163","journal-title":"J Autoimmun"},{"key":"10965_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells GF, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273\u2013283","journal-title":"Hepatology"},{"key":"10965_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100081","volume":"4","author":"L Montali","year":"2021","unstructured":"Montali L, et al. Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison. J Transl Autoimmun. 2021;4: 100081","journal-title":"J Transl Autoimmun"},{"key":"10965_CR67","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","volume":"17","author":"VS Hegade","year":"2019","unstructured":"Hegade VS, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. Clin Gastroenterol Hepatol. 2019;17:1379-1387.e1373","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10965_CR68","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622\u20131629","journal-title":"Gut"},{"key":"10965_CR69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3:365\u2013381","journal-title":"Hepatol Commun"},{"key":"10965_CR70","unstructured":"Hirschfield G et al (2025) Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus: a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial (GLISTEN). Lancet Gastroenterol Hepatol"},{"key":"10965_CR71","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","volume":"53","author":"H Isayama","year":"2018","unstructured":"Isayama H, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol. 2018;53:1006\u20131034","journal-title":"J Gastroenterol"},{"key":"10965_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103264","volume":"147","author":"X Xu","year":"2024","unstructured":"Xu X, et al. Prevalence and clinical profiles of primary sclerosing cholangitis in China: data from electronic medical records and systematic literature retrieval. J Autoimmun. 2024;147: 103264","journal-title":"J Autoimmun"},{"key":"10965_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02265-5","author":"I Naitoh","year":"2025","unstructured":"Naitoh I, et al. The 2024 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol. 2025. https:\/\/doi.org\/10.1007\/s00535-025-02265-5","journal-title":"J Gastroenterol"},{"key":"10965_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100595","volume":"4","author":"A Grigoriadis","year":"2022","unstructured":"Grigoriadis A, et al. Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep. 2022;4: 100595","journal-title":"JHEP Rep"},{"key":"10965_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10050268","author":"T Fujisawa","year":"2020","unstructured":"Fujisawa T, et al. Role of peroral cholangioscopy in the diagnosis of primary sclerosing cholangitis. Diagnostics (Basel). 2020. https:\/\/doi.org\/10.3390\/diagnostics10050268","journal-title":"Diagnostics (Basel)"},{"key":"10965_CR76","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00535-024-02169-w","volume":"60","author":"M Yasuda","year":"2025","unstructured":"Yasuda M, et al. Anti-integrin \u03b1v\u03b26 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study. J Gastroenterol. 2025;60:118\u2013126","journal-title":"J Gastroenterol"},{"key":"10965_CR77","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","volume":"57","author":"T Arizumi","year":"2022","unstructured":"Arizumi T, et al. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. J Gastroenterol. 2022;57:902\u2013912","journal-title":"J Gastroenterol"},{"key":"10965_CR78","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160:734-743.e736","journal-title":"Gastroenterology"},{"key":"10965_CR79","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jhbp.281","volume":"22","author":"S Mizuno","year":"2015","unstructured":"Mizuno S, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22:766\u2013770","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10965_CR80","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jhbp.913","volume":"28","author":"T Nakazawa","year":"2021","unstructured":"Nakazawa T, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012). J Hepatobiliary Pancreat Sci. 2021;28:235\u2013242","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10965_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jhbp.596","volume":"26","author":"T Kamisawa","year":"2019","unstructured":"Kamisawa T, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019;26:9\u201342","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10965_CR82","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","volume":"134","author":"A Ghazale","year":"2008","unstructured":"Ghazale A, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706\u2013715","journal-title":"Gastroenterology"},{"key":"10965_CR83","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00535-020-01714-7","volume":"55","author":"AH Ali","year":"2020","unstructured":"Ali AH, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. J Gastroenterol. 2020;55:1087\u20131097","journal-title":"J Gastroenterol"},{"key":"10965_CR84","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Kremer AE, Levy C. Phase 3 trials of elafibranor and seladelpar for primary biliary cholangitis. Reply. N Engl J Med. 2024;390:1934\u20131935","journal-title":"N Engl J Med"},{"key":"10965_CR85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","volume":"76","author":"R Vuppalanchi","year":"2022","unstructured":"Vuppalanchi R, et al. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022;76:75\u201385","journal-title":"J Hepatol"},{"key":"10965_CR86","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/liv.15596","volume":"43","author":"P Invernizzi","year":"2023","unstructured":"Invernizzi P, et al. Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial. Liver Int. 2023;43:1507\u20131522","journal-title":"Liver Int"},{"key":"10965_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000057","volume":"7","author":"D Jones","year":"2023","unstructured":"Jones D, et al. Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatol Commun. 2023;7: e0057","journal-title":"Hepatol Commun"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10965-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:02:06Z","timestamp":1772056926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10965"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10965-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Atsushi Tanaka, Sombat Treeprasertsuk, Ming-Ling Chang, Soek-Siam Tan, Cumali Efe, Sook-Hyang Jeong, Xiong Ma, Martin Weltman, Hiroyuki Isayama and Jidong Jia have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}